Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer

Zhong,Ailing; Zhang,Hongqin; Xie,Suhong; Deng,Minjie; Zheng,Hui; Wang,Yanchun; Chen,Miaomiao; Lu,Renquan; Guo,Lin

doi:10.3892/or.2018.6229

Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer

Authors:
- Ailing Zhong
- Hongqin Zhang
- Suhong Xie
- Minjie Deng
- Hui Zheng
- Yanchun Wang
- Miaomiao Chen
- Renquan Lu
- Lin Guo
View Affiliations

Affiliations: Department of Clinical Laboratory, Fudan University, Shanghai Cancer Center, Shanghai, P.R. China
Published online on: January 22, 2018 https://doi.org/10.3892/or.2018.6229
Pages: 1747-1756

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysfunction of the DNA repair pathway contributes to tumorigenesis and drug resistance. Methyl methanesulfonate and ultraviolet sensitive gene clone 81 (MUS81), a key endonuclease in DNA repair, is generally considered a tumor suppressor; however, recent studies have revealed its tumor-promoting effect in epithelial ovarian cancer (EOC) and have shown that its overexpression is associated with cisplatin sensitization. However, the exact functional role of MUS81 and its regulation in relation to chemotherapy sensitivity remains unknown. Our previous study using protein interaction chip revealed that minichromosome maintenance complex component 2 (MCM2) is closely correlated with MUS81. This study aimed to investigate the biological effects and mechanisms of MUS81 on cellular responses to chemotherapeutic drugs. To accomplish this, we downregulated MUS81 and MCM2 in A2780 and SKOV3 ovarian cancer cells using lentivirus-mediated RNAi. Using a qPCR-based HR assay kit to detect HR efficiency. The sensitivity of MUS81 to olaparib was investigated by cell proliferation, colony formation assays and flow cytometry. The results showed that MUS81 modulates MCM2 levels as well as homologous recombination (HR) activity. Moreover, downregulation of MUS81 increased the sensitivity of EOC cells to olaparib by inducing S phase arrest and promoting apoptosis through activation of MCM2. MUS81 may be a potential novel therapeutic target for EOC.

View Figures

View References

1	Salani R and Bristow RE: Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol. 55:75–95. 2012. View Article : Google Scholar : PubMed/NCBI
2	Haber JE and Heyer WD: The fuss about Mus81. Cell. 107:551–554. 2001. View Article : Google Scholar : PubMed/NCBI
3	Boddy MN, Lopez-Girona A, Shanahan P, Interthal H, Heyer WD and Russell P: Damage tolerance protein Mus81 associates with the FHA1 domain of checkpoint kinase Cds1. Mol Cell Bio. 20:8758–8766. 2000. View Article : Google Scholar
4	Hanada K, Budzowska M, Davies SL, van Drunen E, Onizawa H, Beverloo HB, Maas A, Essers J, Hickson ID and Kanaar R: The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nat Struct Mol Biol. 14:1096–1104. 2007. View Article : Google Scholar : PubMed/NCBI
5	Sarbajna S and West SC: Holliday junction processing enzymes as guardians of genome stability. Trends Biochem Sci. 39:409–419. 2014. View Article : Google Scholar : PubMed/NCBI
6	Xie S, Zheng H, Wen X, Sun J, Wang Y, Gao X, Guo L and Lu R: MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer. Biochem Bioph Res Commun. 476:493–500. 2016. View Article : Google Scholar
7	McPherson JP, Lemmers B, Chahwan R, Pamidi A, Migon E, Matysiak-Zablocki E, Moynahan ME, Essers J, Hanada K, Poonepalli A, et al: Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science. 304:1822–1826. 2004. View Article : Google Scholar : PubMed/NCBI
8	Dendouga N, Gao H, Moechars D, Janicot M, Vialard J and McGowan CH: Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol Cell Biol. 25:7569–7579. 2005. View Article : Google Scholar : PubMed/NCBI
9	Ledermann JA: PARP inhibitors in ovarian cancer. Ann Oncol. 27 Suppl 1:i40–i44. 2016. View Article : Google Scholar : PubMed/NCBI
10	Gadducci A and Guerrieri ME: PARP inhibitors in epithelial ovarian cancer: State of art and perspectives of clinical research. Anticancer Res. 36:2055–2064. 2016.PubMed/NCBI
11	Liu FW and Tewari KS: New targeted agents in gynecologic cancers: Synthetic lethality, homologous recombination deficiency, and PARP inhibitors. Curr Treat Option Oncol. 17:122016. View Article : Google Scholar
12	McLachlan J and Banerjee S: Olaparib for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother. 17:995–1003. 2016. View Article : Google Scholar : PubMed/NCBI
13	Gunderson CC and Moore KN: Olaparib: An oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Future Oncol. 11:747–757. 2015. View Article : Google Scholar : PubMed/NCBI
14	Negrini S, Gorgoulis VG and Halazonetis TD: Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 11:220–228. 2010. View Article : Google Scholar : PubMed/NCBI
15	Grady WM: Genomic instability and colon cancer. Cancer Metastasis Rev. 23:11–27. 2004. View Article : Google Scholar : PubMed/NCBI
16	Tercero JA, Longhese MP and Diffley JF: A central role for DNA replication forks in checkpoint activation and response. Mol Cell. 11:1323–1336. 2003. View Article : Google Scholar : PubMed/NCBI
17	Sabatinos SA, Green MD and Forsburg SL: Continued DNA synthesis in replication checkpoint mutants leads to fork collapse. Mol Cell Biol. 32:4986–4997. 2012. View Article : Google Scholar : PubMed/NCBI
18	Chen XB, Melchionna R, Denis CM, Gaillard PH, Blasina A, Van de Weyer I, Boddy MN, Russell P, Vialard J and McGowan CH: Human Mus81-associated endonuclease cleaves holliday junctions in vitro. Mol Cell. 8:1117–1127. 2001. View Article : Google Scholar : PubMed/NCBI
19	Boddy MN, Gaillard PH, McDonald WH, Shanahan P, Yates JR III and Russell P: Mus81-Eme1 are essential components of a holliday junction resolvase. Cell. 107:537–548. 2001. View Article : Google Scholar : PubMed/NCBI
20	Fu H, Martin MM, Regairaz M, Huang L, You Y, Lin CM, Ryan M, Kim R, Shimura T, Pommier Y and Aladjem MI: The DNA repair endonuclease Mus81 facilitates fast DNA replication in the absence of exogenous damage. Nat Commun. 6:67462015. View Article : Google Scholar : PubMed/NCBI
21	Blow JJ and Dutta A: Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol. 6:476–486. 2005. View Article : Google Scholar : PubMed/NCBI
22	Sun J, Fernandez-Cid A, Riera A, Tognetti S, Yuan Z, Stillman B, Speck C and Li H: Structural and mechanistic insights into Mcm2-7 double-hexamer assembly and function. Genes Dev. 28:2291–2303. 2014. View Article : Google Scholar : PubMed/NCBI
23	Cortez D, Glick G and Elledge SJ: Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci USA. 101:pp. 10078–10083. 2004; View Article : Google Scholar : PubMed/NCBI
24	Liu M, Ba Z, Costa-Nunes P, Wei W, Li L, Kong F, Li Y, Chai J, Pontes O and Qi Y: IDN2 interacts with RPA and facilitates DNA double-strand break repair by homologous recombination in arabidopsis. Plant Cell. 29:589–599. 2017. View Article : Google Scholar : PubMed/NCBI
25	Maher RL, Branagan AM and Morrical SW: Coordination of DNA replication and recombination activities in the maintenance of genome stability. J Cell Biochem. 112:2672–2682. 2011. View Article : Google Scholar : PubMed/NCBI
26	Mao P, Liu J, Zhang Z, Zhang H, Liu H, Gao S, Rong YS and Zhao Y: Homologous recombination-dependent repair of telomeric DSBs in proliferating human cells. Nat Commun. 7:121542016. View Article : Google Scholar : PubMed/NCBI
27	Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB and Gore ME: ‘BRCAness’ syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 26:5530–5536. 2008. View Article : Google Scholar : PubMed/NCBI
28	Krajewska M, Fehrmann RS, de Vries EG and van Vugt MA: Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet. 6:962015. View Article : Google Scholar : PubMed/NCBI
29	Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
30	Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
31	Remus D, Beuron F, Tolun G, Griffith JD, Morris EP and Diffley JF: Concerted loading of MCM2-7 double hexamers around DNA during DNA replication origin licensing. Cell. 139:719–730. 2009. View Article : Google Scholar : PubMed/NCBI
32	Labib K: How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes Dev. 24:1208–1219. 2010. View Article : Google Scholar : PubMed/NCBI
33	Tercero JA, Labib K and Diffley JF: DNA synthesis at individual replication forks requires the essential initiation factor Cdc45p. EMBO J. 19:2082–2093. 2000. View Article : Google Scholar : PubMed/NCBI
34	Moyer SE, Lewis PW and Botchan MR: Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proc Natl Acad Sci USA. 103:pp. 10236–10241. 2006; View Article : Google Scholar : PubMed/NCBI
35	Rodriguez R, Gagou ME and Meuth M: Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45. Cell Death Differ. 15:889–898. 2008. View Article : Google Scholar : PubMed/NCBI
36	Köhler C, Koalick D, Fabricius A, Parplys AC, Borgmann K, Pospiech H and Grosse F: Cdc45 is limiting for replication initiation in humans. Cell Cycle. 15:974–985. 2016. View Article : Google Scholar : PubMed/NCBI